Armata Pharmaceuticals (ARMP) News Today $3.23 +0.06 (+1.89%) As of 12:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartHeadlinesOwnershipSEC FilingsShort InterestBuy This Stock ARMP Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Decreases By 25.7%September 18, 2025 | marketbeat.comArmata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Down 1.1% - Here's WhySeptember 10, 2025 | marketbeat.comArmata Pharmaceuticals announces publication on phage Pa223September 8, 2025 | msn.comArmata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular BiologySeptember 8, 2025 | prnewswire.comArmata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 4, 2025 | prnewswire.comHC Wainwright Comments on Armata Pharmaceuticals Q3 EarningsAugust 17, 2025 | marketbeat.comArmata Pharmaceuticals (NYSEAMERICAN:ARMP) Trading 0.8% Higher - Should You Buy?August 17, 2025 | marketbeat.comArmata Pharmaceuticals files $100M mixed securities shelfAugust 14, 2025 | msn.comArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate UpdateAugust 13, 2025 | finanznachrichten.deArmata Pharmaceuticals Secures $15M Loan for DevelopmentAugust 12, 2025 | msn.comArmata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate UpdateAugust 12, 2025 | prnewswire.comArmata Pharmaceuticals (ARMP) Projected to Post Earnings on TuesdayAugust 6, 2025 | marketbeat.comArmata Pharmaceuticals (NYSEAMERICAN:ARMP) Stock Price Down 3.6% - Here's WhyJuly 26, 2025 | marketbeat.comArmata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Up 11.9% - Time to Buy?July 4, 2025 | marketbeat.comArmata Pharmaceuticals Inc.July 3, 2025 | barrons.comArmata Pharmaceuticals (NYSEAMERICAN:ARMP) Trading Down 0.5% - Should You Sell?June 12, 2025 | marketbeat.comShort Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Grows By 4,157.1%June 11, 2025 | marketbeat.comArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Sees Significant Decrease in Short InterestJune 1, 2025 | marketbeat.comArmata Pharmaceuticals Q4 EPS Lowered by HC WainwrightMay 23, 2025 | marketbeat.comArmata Pharmaceuticals Insider Trading Activity | AMEX:ARMP | BenzingaMay 20, 2025 | benzinga.comArmata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus BacteremiaMay 19, 2025 | prnewswire.comArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate UpdateMay 16, 2025 | finanznachrichten.deArmata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate UpdateMay 14, 2025 | prnewswire.comArmata Pharmaceuticals secures additional DoD fundingMay 3, 2025 | uk.investing.comArmata Pharmaceuticals (ARMP) Expected to Announce Earnings on TuesdayMay 1, 2025 | marketbeat.comArmata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02May 1, 2025 | prnewswire.comShort Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Expands By 28.3%April 1, 2025 | marketbeat.comHC Wainwright Comments on Armata Pharmaceuticals Q1 EarningsMarch 24, 2025 | marketbeat.comArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate UpdateMarch 21, 2025 | finanznachrichten.deArmata Pharmaceuticals reports Q4 EPS (23c) vs (55c) last yearMarch 21, 2025 | markets.businessinsider.comArmata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate UpdateMarch 20, 2025 | prnewswire.comArmata Pharmaceuticals (ARMP) Projected to Post Quarterly Earnings on ThursdayMarch 13, 2025 | marketbeat.comArmata Pharmaceuticals Announces $10 Million Secured Credit Agreement with InnovivaMarch 12, 2025 | prnewswire.comArmata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy SummitMarch 11, 2025 | prnewswire.comArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest UpdateMarch 1, 2025 | marketbeat.comShort Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Rises By 7.5%February 18, 2025 | marketbeat.comShort Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Rises By 203.3%January 14, 2025 | marketbeat.comArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 125.9% in DecemberDecember 27, 2024 | marketbeat.comPromising Phase 2 Results for AP-PA02 Boost Armata Pharmaceuticals’ Investment AppealDecember 22, 2024 | markets.businessinsider.comArmata Pharma’s inhaled AP-PA02 shows positive results in Phase 2 studyDecember 20, 2024 | finance.yahoo.comArmata Pharmaceuticals (NYSEAMERICAN:ARMP) Earns "Buy" Rating from HC WainwrightDecember 19, 2024 | marketbeat.comArmata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa InfectionDecember 19, 2024 | prnewswire.comSuparna Mishra SarkarDecember 16, 2024 | latimes.comArmata Pharmaceuticals Announces CMO Departure AgreementDecember 5, 2024 | markets.businessinsider.comArmata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual MeetingNovember 19, 2024 | prnewswire.comArmata Pharmaceuticals FY2024 EPS Raised by HC WainwrightNovember 18, 2024 | marketbeat.comArmata Pharmaceuticals Extends Credit Agreement and CMO DepartsNovember 15, 2024 | markets.businessinsider.comArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate UpdateNovember 15, 2024 | finanznachrichten.deArmata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate UpdateNovember 13, 2024 | prnewswire.comArmata Pharmaceuticals (NYSEAMERICAN:ARMP) Receives Buy Rating from HC WainwrightNovember 12, 2024 | marketbeat.com Get Armata Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARMP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARMP Media Mentions By Week ARMP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARMP News Sentiment▼-1.000.77▲Average Medical News Sentiment ARMP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARMP Articles This Week▼01▲ARMP Articles Average Week Get the Latest News and Ratings for ARMP and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Armata Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Alumis News Today PureTech Health News Today 4D Molecular Therapeutics News Today DBV Technologies News Today Lexeo Therapeutics News Today Korro Bio News Today Upexi News Today I-Mab News Today Evolus News Today Larimar Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSEAMERICAN:ARMP) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Armata Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Armata Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
